Back to LLY
LLY Stock: Growth, Valuation and Risks
$LLYNEUTRALDrug Manufacturers—General

LLY Stock: Growth, Valuation and Risks

Eli Lilly's latest reported quarter exceeded EPS estimates, and new manufacturing investment and wider access to obesity medicines support its growth story. At $1,443.50 as of Friday, November 13, the share price is close to the supplied analyst consensus mean, while a high earnings multiple and execution risks complicate the outlook.

November 14, 202610 min read
Current Price
$1443.50
+1.26%
Analyst Rating
Strong Buy
Price Target
$1442.44
-0.1% upside
P/E Ratio
46.73

Executive Summary

Investment Thesis: Eli Lilly's diabetes and obesity franchises, including Mounjaro and Zepbound, sit within a fast-growing market, while recent revenue growth and a Q3 2026 earnings beat point to continuing business momentum. The company is investing in production capacity and broadening access, including a reported partnership with Hims & Hers. Those strengths are balanced by a valuation that assumes sustained growth, uncertain competitive and regulatory outcomes, and analyst targets that are close to the current share price on the supplied consensus data.

Current Price: $1,443.50 as of Friday, November 13 | Key Metric: P/E 46.73 | Stance: NEUTRAL

Company Overview

Eli Lilly and Company is a global pharmaceutical manufacturer based in the United States. Its portfolio spans diabetes, obesity, oncology, immunology and neuroscience, with a particularly prominent position in incretin medicines used to treat type 2 diabetes and obesity.

Key Products & Competitive Position

  • Core Business: Research, development, manufacturing and sale of prescription medicines. Diabetes and obesity treatments are important growth drivers.
  • Key Products: Mounjaro and Zepbound are key incretin products; Lilly also sells medicines across other therapeutic areas. Foundayo is mentioned in the supplied Hims & Hers partnership report.
  • Competitive Moat: Lilly's research capabilities, clinical development experience, established commercial infrastructure and manufacturing investment support its position. Patent protection and scale matter, although neither removes the risks of new competitors or future patent expirations.

Recent Developments

On November 12, Lilly announced a $3.5 billion manufacturing site in Pennsylvania's Lehigh Valley, intended to produce injectable medicines, including retatrutide, and create 850 permanent jobs alongside 2,000 construction jobs. The company described it as the latest of 10 new U.S. sites since 2020. On November 13, reports said Hims & Hers would offer FDA-approved Lilly weight-loss medicines, a development that may broaden patient access while making distribution and affordability important points to monitor.

Financial Snapshot

Market Cap$1,357.97B
P/E Ratio46.73
52-Week Range$850.51 - $1,460
Dividend Yield0.48%
EPS (TTM)$30.92
ROE83.65%

Revenue & Earnings Trends

Third-party financial data supplied with this report shows trailing revenue of approximately $86.46 billion, revenue growth of 38.6%, and earnings growth of 16.3%. These figures indicate rapid expansion, though the growth rates are not a guarantee of future results and can be affected by product supply, pricing, reimbursement and competition. The reported trailing EPS is $30.92 in the supplied key metrics; another Yahoo Finance extract lists $30.81, a small source variation worth noting.

For the quarter reported October 29, 2026, Lilly posted EPS of $7.48 against an estimate of $5.71, an earnings beat of $1.77, or about 31%. That result is positive evidence, but EPS alone doesn't show the full drivers of performance. Revenue mix, costs of expanding production and management's forward commentary will help investors assess whether earnings growth is keeping pace with sales.

Balance Sheet Highlights

The supplied financial extract reports a current ratio of 1.39, total cash of about $4.89 billion, total debt near $49.50 billion and debt-to-equity of 122.93%. Operating cash flow is reported at approximately $30.65 billion, compared with free cash flow of about $9.34 billion. The gap highlights the capital demands of a business investing heavily in manufacturing and development. The current ratio is above 1, but the quick ratio of 0.64 in the same extract suggests that near-term liquidity measures depend partly on current assets beyond cash and receivables.

Valuation Analysis

Current Valuation Metrics

Forward P/E28.5vs Industry: not supplied
PEG Ratio1.32Growth-adjusted
EV/EBITDA28.6vs Historical: not supplied
P/S Ratio15.7vs Peers: not supplied

Historical Comparison

The supplied data does not provide a consistent five-year average for LLY's valuation multiples or a directly comparable industry benchmark, so a precise historical premium or discount cannot be calculated here. A 46.73 trailing P/E and approximately 28.5 forward P/E indicate that the market is assigning substantial value to expected earnings. That can be supported by rapid growth, but also leaves the share price sensitive to changes in forecasts or investor expectations.

Fair Value Estimate

A simple scenario check illustrates the valuation tension. The supplied analyst mean target of $1,442.44 is about 0.1% below the Friday close of $1,443.50, effectively indicating little difference at the midpoint. A separate Yahoo Finance extract gives a mean target of $1,463.40, roughly 1.4% above the close, showing that estimates differ by source and analyst set. Without a full cash-flow forecast, cost of capital and terminal growth assumptions, a defensible independent DCF value cannot be produced. The high valuation makes realized growth and future margins central to any fair-value assessment.

Competitive Landscape

Market Position

Market Share: Not provided in the source data | Ranking: Among the leading global developers and manufacturers of diabetes and obesity medicines

Key Competitors

Novo Nordisk A/S (NVO)Novo Nordisk competes in diabetes and obesity care with established GLP-1 products and a substantial development pipeline.
$VKTXViking Therapeutics is developing metabolic and obesity treatments; pipeline progress and trial outcomes are key variables.
$GPCRStructure Therapeutics is among the companies advancing oral and other metabolic drug candidates.

Competitive Advantages

  • Research and development: Lilly has substantial drug-development experience and a pipeline that includes next-generation obesity candidates such as retatrutide.
  • Commercial reach: Its established global presence and physician relationships can help bring approved medicines to patients across markets.
  • Capacity investment: New production sites may expand supply over time, although construction and qualification require capital and execution.

Earnings Track Record

Last 4 Quarters: 1 verified beat / 0 verified misses

Recent Earnings History

Q3 2026$7.48 vs $5.71 estBEAT
Q2 2026Not suppliedUNVERIFIED
Q1 2026Not suppliedUNVERIFIED
Q4 2025Not suppliedUNVERIFIED

Guidance Trend

No full-year guidance revision history is included in the supplied data, so the direction of management's latest outlook can't be independently assessed here. Analysts' earnings estimate for the February 3, 2027 report is $11.19 per share, but that is a forecast rather than company guidance. Investors can compare management's next update with that estimate and examine whether demand, supply and investment costs are moving together.

Analyst Sentiment

Consensus Rating: Strong Buy

Strong Buy: 6 Buy: 20 Hold: 4 Sell: 1 Strong Sell: 1

Price Targets

  • Low: $940
  • Mean: $1,442.44, approximately -0.1% implied change from Friday's close
  • High: $1,650

Recent Analyst Actions

The supplied recommendation set shows 26 of 32 analysts at Strong Buy or Buy, four at Hold and two at Sell or Strong Sell. Recent Yahoo Finance data lists price-target increases from Jefferies to $1,700 on November 9, Cantor Fitzgerald to $1,600 on November 2, UBS to $1,625 on October 31 and JPMorgan to $1,650 on October 30. These are attributed analyst views, not guarantees. The target data is not fully consistent across feeds: one extract lists a $1,463.40 mean and $1,570 median from 29 opinions, versus the supplied 32-analyst mean of $1,442.44 and median of $1,440.

Recent News & Catalysts

Key Developments

  • Hims & Hers partnership: A November 13 report says Hims & Hers will offer Lilly's FDA-approved weight-loss medicines, including Zepbound and Foundayo. Patient access may expand, while the effects on distribution, pricing and brand positioning remain to be seen.
  • New Pennsylvania manufacturing site: Lilly announced a $3.5 billion facility on November 12. Its intended role includes production of injectable medicines such as retatrutide, but construction does not immediately add commercial supply.
  • Pipeline and AI attention: Recent coverage highlighted ongoing diabetes and obesity research across Lilly and competitors, as well as the potential role of AI in drug discovery. These are areas to follow, not evidence of a near-term change in revenue or development success.

Upcoming Catalysts

Next Earnings: February 3, 2027, EPS estimate $11.19 | Key Events: Quarterly results and guidance, progress on new manufacturing capacity, obesity pipeline updates and demand or access developments

Technical Outlook

Current Price: $1,443.50 as of Friday, November 13 vs 52-Week High: $1,460 (-1.1% from high)

Trend Analysis

LLY ended Friday near its 52-week high after a reported 1.26% session gain, with a 52-week range of $850.51 to $1,460. The supplied two-year analysis reports an 86.39% total return and a 0.45 beta, though past performance and beta do not establish future direction. US markets are closed Saturday, November 14; Friday's close is the latest regular-session reference, and the next session is Monday, November 16.

Key Levels

  • Resistance: $1,460, the 52-week high; $1,500, a round-number reference
  • Support: Around $1,420, near Friday's reported intraday low; around $1,350, an approximate reference rather than a confirmed chart level

Bull vs Bear Case

Bull Case

  • Demand and growth: Reported revenue growth of 38.6% and the Q3 EPS beat support the view that current products can sustain meaningful expansion.
  • Pipeline and access: Retatrutide development, new production investment and the Hims & Hers arrangement could support future capacity and patient reach, subject to regulatory, clinical and execution outcomes.
  • Analyst scenario: The supplied analyst high target is $1,650, about 14.3% above Friday's close. This is the high end of third-party estimates, not a forecast made here.

Bull Target: $1,650, supplied analyst high target, approximately +14.3%

Bear Case

  • Valuation sensitivity: A trailing P/E of 46.73 and P/S near 15.7 leave room for multiple compression if growth or margins disappoint.
  • Competition and access: Novo Nordisk and newer entrants are pursuing the same metabolic market, while affordability, insurance coverage and supply can limit realized demand.
  • Downside scenario: The supplied analyst low target is $940, approximately 34.9% below Friday's close. It illustrates the range of estimates, not a prediction.

Bear Target: $940, supplied analyst low target, approximately -34.9%

Risks to Consider

  • Valuation Risk: Elevated multiples rely on strong earnings expectations. Slower growth, margin pressure or a higher required return could change how the market values those earnings.
  • Competitive Risk: Other drugmakers are developing competing treatments. Differences in efficacy, tolerability, convenience, price and supply could affect market position.
  • Macro Risk: Interest rates, healthcare spending policies, reimbursement decisions and broader market risk appetite can influence both pharmaceutical sales and high-multiple shares.
  • Execution Risk: Clinical trials can fail, approvals can take time, and manufacturing sites can face construction, qualification or supply-chain delays. A 1.39 current ratio and significant planned investment also make capital allocation worth monitoring.

Bottom Line

Investment Verdict: NEUTRAL

Lilly's reported growth, recent earnings beat, product reach and production expansion create a constructive operating picture, but the valuation is demanding and the supplied analyst mean target is essentially in line with Friday's price. For your assessment, the central question is whether earnings growth and capacity can continue to meet expectations while competition, affordability and execution risks remain manageable. This report is informational and isn't personalized investment advice.

Action Items for Investors

  • Long-term investors: Track the relationship between revenue growth, earnings, free cash flow and spending on capacity rather than relying on headline sales growth alone.
  • Short-term traders: Treat $1,460 as a recent reference high, not a forecast; monitor price and volume around reported levels and upcoming company news. Markets next open Monday, November 16.
  • Risk management: Consider how a high valuation, broad analyst target dispersion and the possibility of clinical or supply setbacks fit within your own risk tolerance and diversification plan.

What to Watch This Week

  • Any company updates on the Pennsylvania site's schedule, investment milestones or production plans.
  • Developments in patient access, payer coverage and distribution following the reported Hims & Hers partnership.
  • LLY's price action after the weekend, with Friday's close and 52-week high as historical reference points, not trading signals.

Share this report

Share this article

Spread the word on social media

Think LLY will outperform? Prove it.

Free practice contests — earn Alpha Coins
Enter a Contest

Disclaimer: StockAlpha.ai content is for informational and educational purposes only. It is not personalized investment advice. Sentiment ratings and market analysis reflect data-driven observations, not buy, sell, or hold recommendations. Always consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.

Spotted something wrong? Report an error.